vida: extract claims from 2026-04-23-oecd-health-at-a-glance-2025-us

- Source: inbox/queue/2026-04-23-oecd-health-at-a-glance-2025-us.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings.md

@@ -1,15 +1,14 @@
 ---
 type: claim
 domain: health
-secondary_domains: [internet-finance, grand-strategy]
+description: CBO and ASPE diverge by $35.7B on GLP-1 Medicare coverage because budget scoring rules structurally discount prevention economics
-description: "CBO and ASPE diverge by $35.7B on GLP-1 Medicare coverage because budget scoring rules structurally discount prevention economics"
 confidence: likely
-source: "ASPE Medicare Coverage of Anti-Obesity Medications analysis (2024-11-01), CBO scoring methodology"
+source: ASPE Medicare Coverage of Anti-Obesity Medications analysis (2024-11-01), CBO scoring methodology
 created: 2026-03-11
-related_claims:
+secondary_domains: ["internet-finance", "grand-strategy"]
-  - divergence-prevention-first-cost-reduction-vs-cost-redistribution
+related_claims: ["divergence-prevention-first-cost-reduction-vs-cost-redistribution"]
-sourced_from:
+sourced_from: ["inbox/archive/health/2024-11-01-aspe-medicare-anti-obesity-medication-coverage.md"]
-- inbox/archive/health/2024-11-01-aspe-medicare-anti-obesity-medication-coverage.md
+related: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "medicaid-glp1-coverage-reversing-through-state-budget-pressure"]
 ---
 
 # Federal budget scoring methodology systematically undervalues preventive interventions because the 10-year scoring window and conservative uptake assumptions exclude long-term downstream savings
@@ -83,3 +82,9 @@ Topics:
 - domains/health/_map
 - core/mechanisms/_map
 - foundations/teleological-economics/_map
+
+## Extending Evidence
+
+**Source:** ITIF August 2025 policy recommendations
+
+ITIF explicitly advocates for 'dynamic scoring' in CBO modeling for GLP-1s, arguing that current static scoring underestimates economic benefits by not accounting for downstream cost reductions. They project 0.4% GDP increase (hundreds of billions in added output) if GLP-1 adoption expands at scale, including reduced healthcare spending, increased workforce productivity, and reduced disability—all benefits excluded from traditional 10-year budget windows.

domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md

@@ -53,3 +53,10 @@ KFF national poll finds only 23% of obese/overweight adults currently taking GLP
 **Source:** ICER White Paper April 2025
 
 ICER's white paper explicitly focuses on 'payer sustainability strategies' rather than access expansion, and was criticized by the National Pharmaceutical Council for 'prioritizing payers over patients.' This institutional framing reveals that even rigorous health economics organizations are working on how to contain access, not expand it, because the cost trajectory threatens plan solvency.
+
+
+## Supporting Evidence
+
+**Source:** ITIF August 2025, cross-referenced with ICER/KFF data
+
+ITIF's 74 million eligible obesity treatment population figure provides the denominator for the 23% access rate documented in KFF polling. The contrast between ITIF's expansive potential framing (133M users, 0.4% GDP impact) and ICER's payer-crisis framing (>10x PMPM cost increase, $300M BCBS loss) represents the same drug viewed from opposite ends of the access gap—population health potential versus payer fiscal reality.

domains/health/us-healthcare-ranks-last-among-peer-nations-despite-highest-spending-because-access-and-equity-failures-override-clinical-quality.md

@@ -1,16 +1,14 @@
 ---
 type: claim
 domain: health
-description: "Commonwealth Fund's 2024 international comparison shows US last overall among 10 peer nations despite ranking second in care process quality, proving structural failures override clinical excellence"
+description: Commonwealth Fund's 2024 international comparison shows US last overall among 10 peer nations despite ranking second in care process quality, proving structural failures override clinical excellence
 confidence: proven
-source: "Commonwealth Fund Mirror Mirror 2024 report (Blumenthal et al, 2024-09-19)"
+source: Commonwealth Fund Mirror Mirror 2024 report (Blumenthal et al, 2024-09-19)
 created: 2026-03-11
-supports:
+supports: ["The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity"]
-- The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity
+reweave_edges: ["The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity|supports|2026-04-07"]
-reweave_edges:
+sourced_from: ["inbox/archive/health/2024-09-19-commonwealth-fund-mirror-mirror-2024.md"]
-- The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity|supports|2026-04-07
+related: ["us-healthcare-ranks-last-among-peer-nations-despite-highest-spending-because-access-and-equity-failures-override-clinical-quality", "nhs-demonstrates-universal-coverage-without-adequate-funding-produces-excellent-primary-care-but-catastrophic-specialty-access", "us-healthspan-lifespan-gap-largest-globally-despite-highest-spending"]
-sourced_from:
-- inbox/archive/health/2024-09-19-commonwealth-fund-mirror-mirror-2024.md
 ---
 
 # US healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality
@@ -57,3 +55,9 @@ Relevant Notes:
 
 Topics:
 - domains/health/_map
+
+## Extending Evidence
+
+**Source:** OECD Health at a Glance 2025, US country profile
+
+OECD 2025 shows US clinical quality is not just adequate but world-leading for acute care (30-day AMI mortality 5.2% vs. OECD 6.5%, stroke 4.5% vs. 7.7%). The ranking failure is driven by preventable mortality (50% worse than OECD) and treatable mortality (23% worse despite highest spending), indicating the problem is prevention infrastructure and access to existing excellent care, not clinical capability.

domains/health/us-healthcare-spending-outcome-paradox-confirms-non-clinical-factors-dominate-population-health.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: "International comparison shows US excels at clinical intervention (AMI/stroke mortality 21% better than OECD) while failing at prevention (preventable mortality 50% worse), despite spending 2.5x the OECD average"
+confidence: proven
+source: OECD Health at a Glance 2025, United States country profile
+created: 2026-04-23
+title: The US healthcare spending/outcome paradox — world-class acute care outcomes with dramatically worse preventable mortality — is the strongest empirical confirmation that non-clinical factors dominate population health
+agent: vida
+sourced_from: health/2026-04-23-oecd-health-at-a-glance-2025-us.md
+scope: causal
+sourcer: OECD
+supports: ["medical-care-explains-only-10-20-percent-of-health-outcomes-because-behavioral-social-and-genetic-factors-dominate-as-four-independent-methodologies-confirm"]
+related: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm", "us-healthcare-ranks-last-among-peer-nations-despite-highest-spending-because-access-and-equity-failures-override-clinical-quality", "us-healthspan-lifespan-gap-largest-globally-despite-highest-spending"]
+---
+
+# The US healthcare spending/outcome paradox — world-class acute care outcomes with dramatically worse preventable mortality — is the strongest empirical confirmation that non-clinical factors dominate population health
+
+The US spends $14,885 per capita on healthcare (2.5x the OECD average of $5,967) and 17.2% of GDP (vs. OECD average 9.3%), yet achieves life expectancy 4.3 years below peer countries (78.4 vs. 82.7 years). The critical finding is the SPLIT in outcomes: the US outperforms on acute clinical care — 30-day AMI mortality is 5.2% vs. OECD average 6.5% (21% better), and 30-day stroke mortality is 4.5% vs. 7.7% (42% better). However, preventable mortality (deaths from conditions where behavioral/environmental intervention works) is 217 per 100,000 vs. OECD average 145 (50% worse), and treatable mortality (deaths where timely clinical care should save lives) is 95 vs. 77 (23% worse). This pattern is exactly what the non-clinical factors hypothesis predicts: excellent clinical performance cannot compensate for structural failures in the behavioral, social, and environmental determinants of health. The US system is optimized for — and excels at — clinical intervention, but this is the wrong lever for improving population health outcomes. The spending is directed almost entirely at clinical care, with minimal investment in prevention and social infrastructure, creating a system that is world-class at treating disease but catastrophically bad at preventing it. The 23% worse treatable mortality despite being the highest spender also suggests access failures prevent even the excellent clinical care from reaching all populations.

entities/health/information-technology-and-innovation-foundation.md

@@ -0,0 +1,24 @@
+# Information Technology and Innovation Foundation (ITIF)
+
+**Type:** Policy research organization  
+**Focus:** Pro-innovation technology policy advocacy  
+**Relevance:** GLP-1 access and economic impact analysis
+
+## Overview
+
+ITIF is a pro-innovation, pro-technology policy organization that produces research and advocacy on technology policy issues. In healthcare, they focus on access expansion and economic impact modeling for transformative therapeutics.
+
+## Timeline
+
+- **2025-08-18** — Published "A Shot at a Healthier Future: The Transformative Potential of GLP-1s" estimating 74M Americans eligible for GLP-1 obesity treatment and projecting 0.4% GDP increase if adoption expands at scale
+
+## Position
+
+ITIF advocates for:
+- Federal coverage expansion (Medicare and Medicaid) for GLP-1s
+- Dynamic scoring in CBO estimates to capture GDP/productivity gains
+- Continued basic research funding for GLP-1 mechanisms and new indications
+
+## Context
+
+ITIF reports should be read as advocacy for innovation adoption and access expansion, not neutral analysis. Their economic projections are modeling exercises rather than observed data, but they usefully quantify the scale of potential societal impact if structural access barriers were overcome.

inbox/archive/health/2026-04-23-itif-glp1-transformative-potential-2025.md

@@ -7,9 +7,12 @@ date: 2025-08-18
 domain: health
 secondary_domains: []
 format: policy report
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-23
 priority: medium
 tags: [glp-1, policy, access, GDP, economic-impact, obesity, coverage, workforce, population-health]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2026-04-23-oecd-health-at-a-glance-2025-us.md

@@ -7,9 +7,12 @@ date: 2025-11-01
 domain: health
 secondary_domains: []
 format: statistical report
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-23
 priority: high
 tags: [OECD, international-comparison, health-spending, outcomes, life-expectancy, preventable-mortality, clinical-effectiveness, US-health-system]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content